Adam Laponis - Oct 8, 2025 Form 4 Insider Report for Twist Bioscience Corp (TWST)

Role
Chief Financial Officer
Signature
/s/ Kendra Fox, as Attorney-in-Fact for Adam Laponis
Stock symbol
TWST
Transactions as of
Oct 8, 2025
Transactions value $
-$176,315
Form type
4
Date filed
10/10/2025, 04:05 PM
Previous filing
Oct 8, 2025
SEC
View on sec.gov

Reporting Owners (1)

Name Relationship Address Signature Signature date CIK
Laponis Adam Chief Financial Officer C/O TWIST BIOSCIENCE CORPORATION, 681 GATEWAY BLVD, SOUTH SAN FRANCISCO /s/ Kendra Fox, as Attorney-in-Fact for Adam Laponis 2025-10-10 0001827198

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction TWST Common Stock Sale -$93.5K -3K -3.09% $31.15 94K Oct 8, 2025 Direct F1
transaction TWST Common Stock Sale -$82.9K -2.52K -2.68% $32.92 91.5K Oct 9, 2025 Direct F2
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Buy Plan / Sale Plan: These are also open market purchases/sales of shares, but in this case the transaction is part of a trading plan. Rule 10b5-1 allows insiders to setup a trading plan to buy/sell stocks over a certain period of time. Since the purchases/sales are predetermined, this protects the insiders from violating insider trading law.

Transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c).

Explanation of Responses:

Id Content
F1 The transaction reported on this Form 4 is effected pursuant to a Rule 10b5-1 trading plan previously adopted by the Reporting Person on May 8, 2025.
F2 Represents the number of shares required to be sold by the Reporting Person to cover tax withholding obligations in connection with the vesting of Restricted Stock Units. These sales are mandated by the Issuer's election under its equity incentive plans to require the satisfaction of a tax withholding obligation to be funded by a "sell to cover" transaction and do not represent discretionary trades by the Reporting Person.